SN1N Stock Chart & Stats
$256.55
$0.00(0.00%)
At close: 4:00 PM EDT
$256.55
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$256.55 - $256.55
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$227.46B
Enterprise Value$12.80K
Total Cash (Recent Filing)$557.20M
Total Debt (Recent Filing)$3.33B
Price to Earnings (P/E)21.1
Beta0.03
Next Earnings
Aug 04, 2026EPS Estimate
8.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding839,857,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.73
Price to Sales (P/S)2.30
P/FCF Ratio16.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$329.95Price Target Upside28.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.26
Revenue Forecast (FY)$1.53B
Bulls Say, Bears Say
Bulls Say
Innovation-led GrowthA large share of recent growth coming from new products signals a durable R&D and commercialization engine. Sustained new-product adoption expands addressable markets, drives recurring consumable sales, and builds clinical differentiation that supports medium-term organic growth and competitive positioning.
Improving Cash GenerationMaterial improvement in operating and free cash flow strengthens long-term financial flexibility. Higher cash generation supports reinvestment in R&D and capex, funds dividends and buybacks, reduces refinancing risk, and gives capacity to execute acquisitions or cost programs without over-leveraging the balance sheet.
Regulatory Milestone (TESSA De Novo)FDA De Novo creates a new device category and provides a first-mover regulatory foothold for intra-articular navigation. This structural approval can embed advanced navigation and AI into Smith & Nephew's ortho offering, enabling system sales, consumable pull-through, and durable differentiation versus peers.
Bears Say
China VBP HeadwindChina volume-based procurement represents a structural pricing and access risk. Even with a modest revenue share, persistent procurement reforms can compress margins and force ongoing price or mix adjustments, making growth and profitability in emerging markets harder to predict and manage over the medium term.
Reimbursement Policy Risk (skin Substitutes)Regulatory changes to reimbursement for skin substitutes are a structural threat to recurring wound-care revenues. Reduced reimbursement undermines unit economics and consumable pull-through, forcing pricing, channel or product strategy shifts that can depress margins and require product or go-to-market adaptation to restore prior profitability levels.
Portfolio Rationalization / Inventory Write-downA large inventory impairment and major SKU cuts highlight executional and demand-forecasting challenges. Impairments weaken working-capital quality, create one-off profit hits, and signal that simplifying the portfolio may take time to restore consistent margins and cash conversion as revenues rebase and operational efficiency is re-established.
Smith & Nephew News
SN1N FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest stock price was $256.55 and its highest was $256.55 in the past 12 months.
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is $227.46B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Aug 04, 2026 which is tomorrow.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Mar 02, 2026. The company reported $10.291 earnings per share for the quarter, beating the consensus estimate of $10.082 by $0.209.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc does not currently pay dividends.
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 8.2.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 839,857,200 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of $10.291 in its last earnings report, beating expectations of $10.082. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in MX:SN1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$329.95 (28.61% Upside)
$329.95 (28.61% Upside)
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.38%
12-Months-Change
Fundamentals
Return on Equity
2.43%
Trailing 12-Months
Asset Growth
-5.96%
Trailing 12-Months
Company Description
Smith & Nephew plc
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
SN1N Stock 12 Month Forecast
Average Price Target
$329.95
▲(28.61% Upside)